Blockchain Registration Transaction Record

Nutriband Secures $5.3M for Abuse-Deterrent Fentanyl Patch Ahead of FDA Filing

Nutriband raises $5.3M for AVERSA™ abuse-deterrent fentanyl patch, targeting FDA submission and $80-200M in peak annual sales for safer pain management.

This development matters because it addresses the critical opioid abuse crisis that has devastated communities worldwide. AVERSA™ represents a potential breakthrough in pain management safety, offering healthcare providers a tool to deliver effective pain relief while reducing the risk of abuse and diversion. For patients suffering from chronic pain, this innovation could mean access to necessary medication with significantly reduced safety concerns. The substantial investor backing also indicates market recognition of both the medical need and commercial potential, suggesting this technology could soon become available to medical professionals and patients, potentially saving lives and reducing opioid-related harm.